Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function

M. A. Morse, A. Hobeika, D. Serra, K. Aird, M. McKinney, A. Aldrich, T. Clay, D. Mourich, H. K. Lyerly, P. L. Iversen, G. R. Devi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

CD4CD25regulatory T cells (T reg) impair anti-tumor and anti-viral immunity. As there are higher T reg levels in cancer patients compared with healthy individuals, there is considerable interest in eliminating them or altering their function as part of cancer or viral immunotherapy strategies. The scurfin transcriptional regulator encoded by the member of the forkhead winged helix protein family (FOXP3) is critical for maintaining the functions of T reg. We hypothesized that targeting FOXP3 expression with a novel arginine-rich, cell-penetrating, peptide-conjugated phosphorodiamidate morpholino (PPMO) based antisense would eliminate T reg and enhance the induction of effector T-cell responses. We observed that the PPMO was taken up by activated T cells in vitro and could downregulate FOXP3 expression, which otherwise increases during antigen-specific T-cell activation. Generation of antigen-specific T cells in response to peptide stimulation was enhanced by pre-treatment of peripheral blood mononuclear cells with the FOXP3-targeted PPMO. In summary, modulation of T reg levels using the FOXP3 PPMO antisense-based genomic strategy has the potential to optimize immunotherapy strategies in cancer and viral immunotherapy.

Original languageEnglish (US)
Pages (from-to)30-37
Number of pages8
JournalCancer gene therapy
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Cell-Penetrating Peptides
Morpholinos
Regulatory T-Lymphocytes
Arginine
Immunotherapy
T-Lymphocytes
Neoplasms
CD27 Antigens
Immunity
Blood Cells
Down-Regulation
Antigens
Peptides
Proteins

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Morse, M. A. ; Hobeika, A. ; Serra, D. ; Aird, K. ; McKinney, M. ; Aldrich, A. ; Clay, T. ; Mourich, D. ; Lyerly, H. K. ; Iversen, P. L. ; Devi, G. R. / Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function. In: Cancer gene therapy. 2012 ; Vol. 19, No. 1. pp. 30-37.
@article{a92fda2d8ccb4483aea6fd838a5644c7,
title = "Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function",
abstract = "CD4CD25regulatory T cells (T reg) impair anti-tumor and anti-viral immunity. As there are higher T reg levels in cancer patients compared with healthy individuals, there is considerable interest in eliminating them or altering their function as part of cancer or viral immunotherapy strategies. The scurfin transcriptional regulator encoded by the member of the forkhead winged helix protein family (FOXP3) is critical for maintaining the functions of T reg. We hypothesized that targeting FOXP3 expression with a novel arginine-rich, cell-penetrating, peptide-conjugated phosphorodiamidate morpholino (PPMO) based antisense would eliminate T reg and enhance the induction of effector T-cell responses. We observed that the PPMO was taken up by activated T cells in vitro and could downregulate FOXP3 expression, which otherwise increases during antigen-specific T-cell activation. Generation of antigen-specific T cells in response to peptide stimulation was enhanced by pre-treatment of peripheral blood mononuclear cells with the FOXP3-targeted PPMO. In summary, modulation of T reg levels using the FOXP3 PPMO antisense-based genomic strategy has the potential to optimize immunotherapy strategies in cancer and viral immunotherapy.",
author = "Morse, {M. A.} and A. Hobeika and D. Serra and K. Aird and M. McKinney and A. Aldrich and T. Clay and D. Mourich and Lyerly, {H. K.} and Iversen, {P. L.} and Devi, {G. R.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1038/cgt.2011.63",
language = "English (US)",
volume = "19",
pages = "30--37",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "1",

}

Morse, MA, Hobeika, A, Serra, D, Aird, K, McKinney, M, Aldrich, A, Clay, T, Mourich, D, Lyerly, HK, Iversen, PL & Devi, GR 2012, 'Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function', Cancer gene therapy, vol. 19, no. 1, pp. 30-37. https://doi.org/10.1038/cgt.2011.63

Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function. / Morse, M. A.; Hobeika, A.; Serra, D.; Aird, K.; McKinney, M.; Aldrich, A.; Clay, T.; Mourich, D.; Lyerly, H. K.; Iversen, P. L.; Devi, G. R.

In: Cancer gene therapy, Vol. 19, No. 1, 01.01.2012, p. 30-37.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function

AU - Morse, M. A.

AU - Hobeika, A.

AU - Serra, D.

AU - Aird, K.

AU - McKinney, M.

AU - Aldrich, A.

AU - Clay, T.

AU - Mourich, D.

AU - Lyerly, H. K.

AU - Iversen, P. L.

AU - Devi, G. R.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - CD4CD25regulatory T cells (T reg) impair anti-tumor and anti-viral immunity. As there are higher T reg levels in cancer patients compared with healthy individuals, there is considerable interest in eliminating them or altering their function as part of cancer or viral immunotherapy strategies. The scurfin transcriptional regulator encoded by the member of the forkhead winged helix protein family (FOXP3) is critical for maintaining the functions of T reg. We hypothesized that targeting FOXP3 expression with a novel arginine-rich, cell-penetrating, peptide-conjugated phosphorodiamidate morpholino (PPMO) based antisense would eliminate T reg and enhance the induction of effector T-cell responses. We observed that the PPMO was taken up by activated T cells in vitro and could downregulate FOXP3 expression, which otherwise increases during antigen-specific T-cell activation. Generation of antigen-specific T cells in response to peptide stimulation was enhanced by pre-treatment of peripheral blood mononuclear cells with the FOXP3-targeted PPMO. In summary, modulation of T reg levels using the FOXP3 PPMO antisense-based genomic strategy has the potential to optimize immunotherapy strategies in cancer and viral immunotherapy.

AB - CD4CD25regulatory T cells (T reg) impair anti-tumor and anti-viral immunity. As there are higher T reg levels in cancer patients compared with healthy individuals, there is considerable interest in eliminating them or altering their function as part of cancer or viral immunotherapy strategies. The scurfin transcriptional regulator encoded by the member of the forkhead winged helix protein family (FOXP3) is critical for maintaining the functions of T reg. We hypothesized that targeting FOXP3 expression with a novel arginine-rich, cell-penetrating, peptide-conjugated phosphorodiamidate morpholino (PPMO) based antisense would eliminate T reg and enhance the induction of effector T-cell responses. We observed that the PPMO was taken up by activated T cells in vitro and could downregulate FOXP3 expression, which otherwise increases during antigen-specific T-cell activation. Generation of antigen-specific T cells in response to peptide stimulation was enhanced by pre-treatment of peripheral blood mononuclear cells with the FOXP3-targeted PPMO. In summary, modulation of T reg levels using the FOXP3 PPMO antisense-based genomic strategy has the potential to optimize immunotherapy strategies in cancer and viral immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=83555172271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83555172271&partnerID=8YFLogxK

U2 - 10.1038/cgt.2011.63

DO - 10.1038/cgt.2011.63

M3 - Article

C2 - 21997230

AN - SCOPUS:83555172271

VL - 19

SP - 30

EP - 37

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 1

ER -